Trials / Completed
CompletedNCT04930965
Impact of LA-CEAL HALT COVID-19 Ambassador Program on Likelihood to Vaccinate
Louisiana Community-Engagement Alliance Against COVID-19 Disparities (LA-CEAL): Impact of HALT COVID Ambassador Program on Likelihood to Vaccinate
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Tulane University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to assess the effectiveness of the HALT COVID Ambassador educational outreach program on increasing likelihood to vaccinate against COVID-19
Detailed description
Investigators will use a randomized controlled trial to test the effectiveness of HALT COVID educational outreach by HALT COVID Ambassadors. HALT COVID Ambassadors will receive training to answer common vaccine questions \& address misconceptions; conduct motivational interviewing; and implement basic behavioral economics and related strategies to remove barriers to vaccination. A random sample of FQHC patients will be identified in EHR data downloads of adult patients seen in the last year and contacted by telephone to gain consent and assess eligibility. A total of 100 individuals will be enrolled into the trial and randomized to intervention (engagement with the HALT COVID Ambassador over a 1 month period via in-person or virtual sessions exploring their own questions and concerns about vaccines) or usual care (no extra engagement). Baseline, 1-month, and 2-month follow-up surveys will assess for vaccine likelihood.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Community health worker engagement | 3-4 in-person or virtual engagements (individual or group sessions) over 1 month, each engagement lasting 30 minutes to 1 hour |
Timeline
- Start date
- 2021-10-05
- Primary completion
- 2022-12-31
- Completion
- 2023-02-28
- First posted
- 2021-06-18
- Last updated
- 2024-01-18
- Results posted
- 2024-01-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04930965. Inclusion in this directory is not an endorsement.